search
Back to results

Validation of Therapeutic Effects of Cefaly on Insomnia

Primary Purpose

Sleep Initiation and Maintenance Disorders

Status
Completed
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Cefaly
Sponsored by
Saint Vincent's Hospital, Korea
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sleep Initiation and Maintenance Disorders

Eligibility Criteria

19 Years - 64 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patients who have adequately understood the whole study procedures within age range of 19-64 years
  2. Patients with insomnia severity index (ISI) score of more than 15

Exclusion Criteria:

  1. Cognitive impairment
  2. Psychiatric disorders or neurological disorders.
  3. Unstable medical conditions
  4. Prior diagnosis of sleep disorders
  5. Hypnotic prescription
  6. History of brain or facial trauma within 3 months
  7. Skin abrasions
  8. Acrylic acid allergy
  9. Electromagnetic hypersensitivity
  10. Apnea hypopnea index of >15/hour in the baseline polysomnography.

Sites / Locations

  • St.Vincent's Hospital, the Catholic University of Korea

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Cefaly Intervention

Arm Description

Cefaly

Outcomes

Primary Outcome Measures

Pittsburgh sleep quality index(PSQI)
Changes in Pittsburgh sleep quality index scores PSQI global score of more than 5 signifies major sleep disturbance, higher scores suggesting greater sleep disturbance.
Insomnia severity index(ISI)
Changes in Insomnia severity index scores ISI is a brief, self-rated scale that is widely used to measure insomnia severity. With seven items scored on a 0-4 scale, it only takes about 5 minutes to complete and scores of 15 or more indicates insomnia of moderate to severe severity.
Epworth sleepiness scale(ESS)
Changes in Epworth sleepiness scale scores Score of more than 10 signifies clinically meaningful daytime sleepiness, with higher scores indicating more severe sleepiness.
Polysomnography measures-1 (Total sleep time)
Changes in Total sleep time
Polysomnography measures-2 (Wake after sleep onset)
Changes in Wake after sleep onset
Polysomnography measures-3( Stage 1 sleep period)
Changes in Stage 1 sleep period
Polysomnography measures-4(Stage 2 sleep period)
Changes in Stage 2 sleep period
Polysomnography measures-5(Stage 3 sleep period)
Changes in Stage 3 sleep period
Polysomnography measures-6(Total rapid eye movement sleep period)
Changes in Total rapid eye movement sleep period
Polysomnography measures-7(Rapid eye movement sleep latency)
Changes in Rapid eye movement sleep latency
Polysomnography measures-8(Sleep latency)
Changes in Sleep latency
Polysomnography measures-9(Apnea hypopnea index)
Changes in Apnea hypopnea index
Neuroimaging parameter changes-1(Resting state network functional connectivity)
Resting state network functional connectivity changes
Neuroimaging parameter changes-2(Cortical thickness)
Changes in Cortical thickness
Neuroimaging parameter changes-4(Fractional anisotropy)
Changes in Fractional anisotropy
Neuroimaging parameter changes-5(Mean diffusivity)
Changes in Mean diffusivity

Secondary Outcome Measures

Full Information

First Posted
April 4, 2021
Last Updated
April 6, 2021
Sponsor
Saint Vincent's Hospital, Korea
search

1. Study Identification

Unique Protocol Identification Number
NCT04838067
Brief Title
Validation of Therapeutic Effects of Cefaly on Insomnia
Official Title
Validation of Therapeutic Effects of Cefaly on Insomnia by Neuroimaging and Polysomnography Analyses: a Single Site, Single-armed Exploratory Study
Study Type
Interventional

2. Study Status

Record Verification Date
April 2021
Overall Recruitment Status
Completed
Study Start Date
July 26, 2018 (Actual)
Primary Completion Date
April 7, 2020 (Actual)
Study Completion Date
July 14, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Saint Vincent's Hospital, Korea

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The study aims to examine whether the Cefaly has a therapeutic effect on insomnia patients visiting a psychiatric clinic in Korea. The study design is a single site, single-armed exploratory study. Insomnia patients received a 20-minute daily sessions of the Cefaly for 4 weeks. Primary endpoint was a reduction of scores in Pittsburgh Sleep Quality Index, Insomnia Severity Index, Epworth Sleepiness Scale, improvements in polysomnography measures, and changes in resting state networks, cortical thickness, fractional anisotropy and mean diffusivity
Detailed Description
Insomnia is well-known for its association with adverse health outcomes. Although insomnia is usually treated with hypnotics or cognitive behavioral therapy for insomnia, the need for novel nonpharmacological treatment for insomnia is increasing emphasized due to reports of side effects and detrimental consequences of hypnotics. Trigeminal nerve electrical neuromodulation has been suggested as a potential treatment modality through its modulation of noradrenergic activity that results in promoting relaxation and reducing hyperarousal. Insomnia patients enrolled in the study will go through a 20-minute daily session of the Cefaly device(originally FDA-approved device for migraine, which electrically modulates trigeminal nerve) for 4 weeks. The objective of this study is to test whether trigeminal nerve electrical neuromodulation has a therapeutic effect, validation measures involving subjective measures(Pittsburgh Sleep Quality Index, Insomnia Severity Index, Epworth Sleepiness Scale), objective measures(Polysomnography measures) and neuroimaging(changes in resting state networks, cortical thickness, fractional anisotropy and mean diffusivity).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sleep Initiation and Maintenance Disorders

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
19 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cefaly Intervention
Arm Type
Experimental
Arm Description
Cefaly
Intervention Type
Device
Intervention Name(s)
Cefaly
Intervention Description
Transcutaneous trigeminal nerve electrical neuromodulation
Primary Outcome Measure Information:
Title
Pittsburgh sleep quality index(PSQI)
Description
Changes in Pittsburgh sleep quality index scores PSQI global score of more than 5 signifies major sleep disturbance, higher scores suggesting greater sleep disturbance.
Time Frame
4 weeks after intervention
Title
Insomnia severity index(ISI)
Description
Changes in Insomnia severity index scores ISI is a brief, self-rated scale that is widely used to measure insomnia severity. With seven items scored on a 0-4 scale, it only takes about 5 minutes to complete and scores of 15 or more indicates insomnia of moderate to severe severity.
Time Frame
4 weeks after intervention
Title
Epworth sleepiness scale(ESS)
Description
Changes in Epworth sleepiness scale scores Score of more than 10 signifies clinically meaningful daytime sleepiness, with higher scores indicating more severe sleepiness.
Time Frame
4 weeks after intervention
Title
Polysomnography measures-1 (Total sleep time)
Description
Changes in Total sleep time
Time Frame
4 weeks after intervention
Title
Polysomnography measures-2 (Wake after sleep onset)
Description
Changes in Wake after sleep onset
Time Frame
4 weeks after intervention
Title
Polysomnography measures-3( Stage 1 sleep period)
Description
Changes in Stage 1 sleep period
Time Frame
4 weeks after intervention
Title
Polysomnography measures-4(Stage 2 sleep period)
Description
Changes in Stage 2 sleep period
Time Frame
4 weeks after intervention
Title
Polysomnography measures-5(Stage 3 sleep period)
Description
Changes in Stage 3 sleep period
Time Frame
4 weeks after intervention
Title
Polysomnography measures-6(Total rapid eye movement sleep period)
Description
Changes in Total rapid eye movement sleep period
Time Frame
4 weeks after intervention
Title
Polysomnography measures-7(Rapid eye movement sleep latency)
Description
Changes in Rapid eye movement sleep latency
Time Frame
4 weeks after intervention
Title
Polysomnography measures-8(Sleep latency)
Description
Changes in Sleep latency
Time Frame
4 weeks after intervention
Title
Polysomnography measures-9(Apnea hypopnea index)
Description
Changes in Apnea hypopnea index
Time Frame
4 weeks after intervention
Title
Neuroimaging parameter changes-1(Resting state network functional connectivity)
Description
Resting state network functional connectivity changes
Time Frame
4 weeks after intervention
Title
Neuroimaging parameter changes-2(Cortical thickness)
Description
Changes in Cortical thickness
Time Frame
4 weeks after intervention
Title
Neuroimaging parameter changes-4(Fractional anisotropy)
Description
Changes in Fractional anisotropy
Time Frame
4 weeks after intervention
Title
Neuroimaging parameter changes-5(Mean diffusivity)
Description
Changes in Mean diffusivity
Time Frame
4 weeks after intervention

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
64 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients who have adequately understood the whole study procedures within age range of 19-64 years Patients with insomnia severity index (ISI) score of more than 15 Exclusion Criteria: Cognitive impairment Psychiatric disorders or neurological disorders. Unstable medical conditions Prior diagnosis of sleep disorders Hypnotic prescription History of brain or facial trauma within 3 months Skin abrasions Acrylic acid allergy Electromagnetic hypersensitivity Apnea hypopnea index of >15/hour in the baseline polysomnography.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Se-Min Choung
Organizational Affiliation
CMC IRB
Official's Role
Study Director
Facility Information:
Facility Name
St.Vincent's Hospital, the Catholic University of Korea
City
Suwon
Country
Korea, Republic of

12. IPD Sharing Statement

Citations:
PubMed Identifier
35619611
Citation
Um YH, Wang SM, Kang DW, Kim NY, Lim HK. Alterations of Resting-State Locus Coeruleus Functional Connectivity After Transdermal Trigeminal Electrical Neuromodulation in Insomnia. Front Psychiatry. 2022 May 10;13:875227. doi: 10.3389/fpsyt.2022.875227. eCollection 2022.
Results Reference
derived
PubMed Identifier
34383274
Citation
Um YH, Wang SM, Kang DW, Kim NY, Lim HK. Impact of transdermal trigeminal electrical neuromodulation on subjective and objective sleep parameters in patients with insomnia: a pilot study. Sleep Breath. 2022 Jun;26(2):865-870. doi: 10.1007/s11325-021-02459-0. Epub 2021 Aug 12.
Results Reference
derived

Learn more about this trial

Validation of Therapeutic Effects of Cefaly on Insomnia

We'll reach out to this number within 24 hrs